aro-aat
Nucleic acidexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Mar 12, 2018 (NCT03362242)
Timeline
Indications
Mechanism of action
- Alpha-1-antitrypsinSupplementation
SERPINA1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095435 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06165341 | Phase 3 | Jan 18, 2024 | Takeda |
| NCT05891158 | Phase 1 | Oct 5, 2023 | Takeda |
| NCT05899673 | Phase 3 | Aug 8, 2023 | Takeda |
| NCT05677971 | Phase 3 | Mar 6, 2023 | Takeda |
| NCT03946449 | Phase 2 | Jul 15, 2019 | Arrowhead Pharmaceuticals |
| NCT03945292 | Phase 2/Phase 3 (Phase 3) | Jun 15, 2019 | Arrowhead Pharmaceuticals |
| NCT03362242 | Phase 1 | Mar 12, 2018 | Arrowhead Pharmaceuticals |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 4 | 4 | 2 | 2023 |
| Arrowhead Pharmaceuticals | For profit | 3 | 3 | 3 | 2018 |
2 organizations
Page 1 / 1